Clinical trial
A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced Intensity Conditioning for Patients With Hematologic Malignancies
NCT03246906 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced Intensity Conditioning for Patients With Hematologic Malignancies
- Lead sponsor
- Fred Hutchinson Cancer Center
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 11, 2017
- Completion date
- May 3, 2025
- Enrollment
- 150 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoblastic leukemia, acute myeloid leukemia, aggressive non-hodgkin lymphoma, blastic plasmacytoid dendritic cell neoplasm, chronic lymphocytic leukemia, diffuse large b-cell lymphoma, hematologic and lymphocytic disorder, mantle cell lymphoma, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, prolymphocytic leukemia, recurrent chronic lymphocytic leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, recurrent hodgkin lymphoma, recurrent plasma cell myeloma, recurrent small lymphocytic lymphoma, recurrent waldenstrom macroglobulinemia